Overview

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Status:
Recruiting
Trial end date:
2025-01-30
Target enrollment:
0
Participant gender:
All
Summary
This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost
Criteria
Inclusion Criteria:

- Diagnosis of either Diagnosis of either open angle glaucoma (OAG) (i.e., primary OAG,
pseudoexfoliation glaucoma, pigmentary glaucoma) or ocular hypertension requiring
intraocular pressure-lowering treatment.

Exclusion Criteria:

- Concurrent or anticipated enrollment in another investigational drug or device study
or participation in such a study within 2 months prior to enrolling in this study.

- Previous administration with Bimatoprost SR in the study eye.